1070 related articles for article (PubMed ID: 27415632)
1. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
2. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
[TBL] [Abstract][Full Text] [Related]
4. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
[TBL] [Abstract][Full Text] [Related]
8. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
9. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
[TBL] [Abstract][Full Text] [Related]
11. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Childs-Kean LM; Hand EO
Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
[TBL] [Abstract][Full Text] [Related]
13. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
16. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
17. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
[TBL] [Abstract][Full Text] [Related]
20. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]